Date of Award
Open Access Thesis
Master of Medical Science (MMSc)
Matthew Burg, PhD
Non-obstructive coronary artery disease is prevalent in the United States and is associated with acute coronary syndrome and heart failure. Despite its prevalence and morbidity, no standard therapy exists for non-obstructive coronary artery disease. The development of non-obstructive coronary artery disease involves coronary microvascular dysfunction, which is primarily driven by endothelial dysfunction. Therefore, exploring therapies to improve endothelial function could benefit patients with coronary microvascular dysfunction. Ticagrelor is a P2Y12 inhibitor that is used for its anti-platelet effects and is also thought to improve endothelial function. Therefore, we propose to investigate the effects of ticagrelor versus placebo on coronary flow reserve, a measure of endothelial function in the coronary blood vessels, via positron emission tomography using a randomized controlled trial double-blind approach. Results from our study will test the feasibility of ticagrelor as a therapy for coronary microvascular dysfunction, a condition that currently lacks any treatment guidelines.
Puvalowski, Sabrina, "Randomized Controlled Trial Examining Ticagrelor Versus Placebo on Coronary Flow Reserve" (2019). Yale School of Medicine Physician Associate Program Theses. 56.
This Article is Open Access